CL2008003615A1 - Composicion farmaceutica transmucosal oral que comprende fenilefrina, o una sal de ella, que esta en forma de tiras, de capa bioadhesiva, de liquido para pulverizar, de pastilla , de gel, de capsulas o de tableta; dispositivo portador. - Google Patents

Composicion farmaceutica transmucosal oral que comprende fenilefrina, o una sal de ella, que esta en forma de tiras, de capa bioadhesiva, de liquido para pulverizar, de pastilla , de gel, de capsulas o de tableta; dispositivo portador.

Info

Publication number
CL2008003615A1
CL2008003615A1 CL2008003615A CL2008003615A CL2008003615A1 CL 2008003615 A1 CL2008003615 A1 CL 2008003615A1 CL 2008003615 A CL2008003615 A CL 2008003615A CL 2008003615 A CL2008003615 A CL 2008003615A CL 2008003615 A1 CL2008003615 A1 CL 2008003615A1
Authority
CL
Chile
Prior art keywords
phenylephrine
pharmaceutical composition
lozenge
capsule
strips
Prior art date
Application number
CL2008003615A
Other languages
English (en)
Spanish (es)
Inventor
David Monteith
John O'mullane
Joseph P Reo
Dennis Nelson
Jiansheng Wan
Xiaoming Chen
Mohammed A Kabir
Original Assignee
Msd Consumer Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40510498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Msd Consumer Care Inc filed Critical Msd Consumer Care Inc
Publication of CL2008003615A1 publication Critical patent/CL2008003615A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2008003615A 2007-12-07 2008-12-04 Composicion farmaceutica transmucosal oral que comprende fenilefrina, o una sal de ella, que esta en forma de tiras, de capa bioadhesiva, de liquido para pulverizar, de pastilla , de gel, de capsulas o de tableta; dispositivo portador. CL2008003615A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1222307P 2007-12-07 2007-12-07

Publications (1)

Publication Number Publication Date
CL2008003615A1 true CL2008003615A1 (es) 2009-10-16

Family

ID=40510498

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003615A CL2008003615A1 (es) 2007-12-07 2008-12-04 Composicion farmaceutica transmucosal oral que comprende fenilefrina, o una sal de ella, que esta en forma de tiras, de capa bioadhesiva, de liquido para pulverizar, de pastilla , de gel, de capsulas o de tableta; dispositivo portador.

Country Status (17)

Country Link
US (1) US20090280160A1 (enExample)
EP (1) EP2237767A1 (enExample)
JP (1) JP2011506337A (enExample)
KR (1) KR20100102632A (enExample)
CN (1) CN101938991A (enExample)
AR (1) AR069572A1 (enExample)
AU (1) AU2008335464A1 (enExample)
BR (1) BRPI0820673A2 (enExample)
CA (1) CA2709208A1 (enExample)
CL (1) CL2008003615A1 (enExample)
CO (1) CO6321221A2 (enExample)
MX (1) MX2010006284A (enExample)
PE (1) PE20091084A1 (enExample)
RU (1) RU2010127737A (enExample)
TW (1) TW200932208A (enExample)
WO (1) WO2009076165A1 (enExample)
ZA (1) ZA201004654B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014127118A1 (en) 2013-02-13 2014-08-21 The Procter & Gamble Company Anise flavored medication
US20190008759A1 (en) * 2014-07-03 2019-01-10 Darren Rubin Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN122182527A (zh) * 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
AU2018208531A1 (en) 2017-01-11 2019-06-13 Ferring B.V. A fast disintegrating pharmaceutical composition
WO2019021476A1 (ja) * 2017-07-28 2019-01-31 社会医療法人蘇西厚生会 まつなみリサーチパーク アレルギー症状の予防又は治療剤
CN111465391A (zh) * 2017-09-27 2020-07-28 阿奎斯蒂弗医疗股份有限公司 具有增强的递送的肾上腺素和前药的组合物
IL279713B2 (en) 2018-06-27 2025-01-01 Bioxcel Therapeutics Inc Dexmedetomidine-containing layer compositions and methods for their production
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. TREATMENT SCHEMES FOR NON-SEDATING DEXMEDETOMIDIN
EP4157451B1 (en) * 2020-06-02 2024-12-04 Mohamed Hussein Hamdan Sublingual formulation for hypotension and syncope
US12286451B2 (en) 2020-11-23 2025-04-29 Medtech Products Inc. Borate ester complexes of α-hydroxy carboxylic acids and their conjugate base buffers
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US5025019A (en) * 1984-04-09 1991-06-18 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4623664A (en) * 1985-10-31 1986-11-18 University Of Iowa Research Foundation Oil suspended phenylephrine
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE9190107U1 (de) * 1990-08-07 1993-12-16 Pfizer Inc., New York, N.Y. Abgabe-Vorrichtung mit durch Grenzflächen-Polymerisation erhaltenen Membranen
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
GB9422571D0 (en) * 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
NL1005394C1 (nl) * 1996-04-01 1997-10-02 Kokbing Lo Bevestigingselement en band bevestigd met bevestigingselement.
DE69735552T3 (de) * 1996-12-23 2009-08-13 S.L.A. Pharma Ag Pharmazeutische zubereitung zur behandlung der analinkontinenz und analem juckreiz
DE69833000T2 (de) * 1997-09-26 2006-09-07 Noven Pharmaceuticals, Inc., Miami Bio-klebemittelzusammensetzungen
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6521254B2 (en) * 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6267986B1 (en) * 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2003009834A1 (en) * 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
WO2003019948A1 (en) * 2001-08-27 2003-03-06 Koninklijke Philips Electronics N.V. Video data processor
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030083354A1 (en) * 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US20030114535A1 (en) * 2001-12-14 2003-06-19 Jame Fine Chemicals, Inc. Dextrochlorpheniramine tannate
US20040122107A1 (en) * 2002-09-13 2004-06-24 Fine Jeffrey R Method of alleviating barometric-induced symptoms in airline passengers
JP2004121962A (ja) * 2002-10-01 2004-04-22 National Institute Of Advanced Industrial & Technology ナノバブルの利用方法及び装置
US6979689B2 (en) * 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20070219253A1 (en) * 2003-09-17 2007-09-20 Gul Balwani Decongestant / antihistaminic / expectorant compositions
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20070110689A1 (en) * 2004-01-15 2007-05-17 Mark Feldschuh Oral anaesthetic gel
NZ555909A (en) * 2004-12-13 2009-11-27 Mcneil Ppc Inc Compositions and methods for reducing the degradation of phenylephrine by oxygen
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
CA2612179C (en) * 2005-06-17 2016-08-02 Aft Pharmaceuticals Limited A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US9005652B2 (en) * 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
US7378082B1 (en) * 2007-11-05 2008-05-27 Inspire Pharmaceuticals, Inc. Method for treating allergic rhinitis without adverse effects

Also Published As

Publication number Publication date
US20090280160A1 (en) 2009-11-12
MX2010006284A (es) 2010-09-07
ZA201004654B (en) 2011-03-30
RU2010127737A (ru) 2012-01-20
PE20091084A1 (es) 2009-07-23
CO6321221A2 (es) 2011-09-20
EP2237767A1 (en) 2010-10-13
JP2011506337A (ja) 2011-03-03
KR20100102632A (ko) 2010-09-24
AU2008335464A1 (en) 2009-06-18
BRPI0820673A2 (pt) 2015-06-16
AR069572A1 (es) 2010-02-03
CN101938991A (zh) 2011-01-05
TW200932208A (en) 2009-08-01
WO2009076165A1 (en) 2009-06-18
CA2709208A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
ES2543977T3 (es) Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
CL2011000935A1 (es) Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor.
AR076540A1 (es) Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor
BRPI0915386B8 (pt) Dispositivo para aplicação de um agente ativo através de mucosa
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
ECSP099629A (es) Composición farmacéutica
ECSP11011289A (es) Formulaciones galénicas de compuestos orgánicos
AR069572A1 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
JP2009536147A5 (enExample)
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
AR075369A1 (es) Comprimidos para terapia de combinacion para el tratamiento de infecciones virales.
MX2009005339A (es) Suspensiones analgesicas de liberacion modificada.
DE602007007991D1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
MX2010001839A (es) Metodo y aparato para comunicacion y metodo y aparato para controlar comunicacion.
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
CL2009001556A1 (es) Sistema de administración transdermica de fármacos que comprende una capa que contiene fármaco que comprende una matriz polimérica que contiene estradiol como unico fármaco; método de elaboración; útil para administrar estradiol.
AR082167A1 (es) Formas de dosificacion gastrorretentivas
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
AR055412A1 (es) Preparacion farmaceutica adhesiva que contiene bisoprolol
PE20090625A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
BRPI0509971A (pt) uma forma de dosagem farmacêutica, comprimido e método de preparação
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron